Unmasking of α-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization

Journal of Immunology

Volumn 178, Issue 3, 2007, Pages 1914-1922

  Ayaru, Lakshmana ^a   Pereira, Stephen P ^a   Alisa, Akeel ^a   Pathan, Ansar A ^d   Williams, Roger ^a   Davidson, Brian ^b   Burroughs, Andrew K ^c   Meyer, Tim ^b   Behboudi, Shahriar ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 5; POLYVINYL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR NECROSIS;

EID: 33846480090     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.3.1914     Document Type: Article

References (40)

1. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
2. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
3. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
4. Kotera, Y., K. Shimizu, and J. J. Mule. 2001. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 61: 8105-8109.
5. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191: 423-434.
6. Llovet, J. M., and J. Bruix. 2003. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442.
7. Bruix, J., M. Sala, and J. M. Llovet. 2004. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127: S179-188.
8. Um, S. H., C. Mulhall, A. Alisa, A. R. Ives, J. Karani, R. Williams, A. Bertoletti, and S. Behboudi. 2004. α-Fetoprotein impairs APC function and induces their apoptosis. J. Immunol. 173: 1772-1778.
9. Bruix, J., M. Sherman, J. M. Llovet, M. Beaugrand, R. Lencioni, A. K. Burroughs, E. Christensen, L. Pagliaro, M. Colombo, and J. Rodes. 2001. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 European Association for the Study of the Liver conference. J. Hepatol. 35: 421-430.
10. Grimm, C. F., D. Ortmann, L. Mohr, S. Michalak, T. U. Krohne, S. Meckel, S. Eisele, J. Encke, H. E. Blum, and M. Geissler. 2000. Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119: 1104-1112.
11. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
12. Hanke, P., C. Rabe, M. Serwe, S. Bohm, C. Pagenstecher, T. Sauerbruch, and W. H. Caselmann. 2002. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human α-fetoprotein. Scand. J. Gastroenterol. 37: 949-955.
13. Butterfield, L. H., W. S. Meng, A. Koh, C. M. Vollmer, A. Ribas, V. B. Dissette, K. Faull, J. A. Glaspy, W. H. McBride, and J. S. Economou. 2001. T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein. J. Immunol. 166: 5300-5308.
14. Butterfield, L. H., A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, and J. S. Economou. 2003. T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9: 5902-5908.
15. Liu, Y., S. Daley, V. N. Evdokimova, D. D. Zdobinski, D. M. Potter, and L. H. Butterfield. 2006. Hierarchy of a fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J. Immunol. 177: 712-721.
16. + patients with hepatocellular carcinoma. Int. J. Cancer 118: 1194-1204.
17. + T lymphocytes. Nature 421: 852-856.
18. + T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 109: 1463-1470.
19. + T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Invest. 114: 542-550.
20. + T-Cell responses to a novel α-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin. Cancer Res. 11: 6686-6694.
21. Ebied, O. M., M. P. Federle, B. I. Carr, K. M. Pealer, W. Li, N. Amesur, and A. Zajko. 2003. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 97: 1042-1050.
22. Hurley, C. K., J. A. Wade, M. Oudshoorn, D. Middleton, D. Kukuruga, C. Navarrete, F. Christiansen, J. Hegland, E. C. Ren, I. Andersen, et al. 1999. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hum. Immunol. 60: 347-360.
23. Bunce, M., C. M. O'Neill, M. C. Barnardo, P. Krausa, M. J. Browning, P. J. Morris, and K. I. Welsh. 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46: 355-367.
24. Bodmer, J. G., S. G. Marsh, E. D. Albert, W. F. Bodmer, R. E. Bontrop, D. Charron, B. Dupont, H. A. Erlich, R. Fauchet, B. Mach, et al. 1997. Nomenclature for factors of the HLA system, 1996. Eur. J. Immunogenet. 24: 105-151.
25. Nagorsen, D., C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz. 2003. Natural T cell immunity against cancer. Clin. Cancer Res. 9: 4296-4303.
26. Knutson, K. L., and M. L. Disis. 2005. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728.
27. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10: 588-594.
28. + T cell to a fully functional tumor killer cell. Cancer Res. 62: 6438-6441.
29. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
30. Knutson, K. L., K. Schiffman, M. A. Cheever, and M. L. Disis. 2002. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8: 1014-1018.
31. Knutson, K. L., K. Schiffman, and M. L. Disis. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107: 477-484.
32. Korangy, F., L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten. 2004. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10: 4332-4341.
33. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62: 3630-3635.
34. Matoba, K., N. Iizuka, T. Gondo, T. Ishihara, H. Yamada-Okabe, T. Tamesa, N. Takemoto, K. Hashimoto, K. Sakamoto, T. Miyamoto, et al. 2005. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int. J. Cancer 115: 231-240.
35. den Brok, M. H., R. P. Sutmuller, R. van der Voort, E. J. Bennink, C. G. Figdor, T. J. Ruers, and G. J. Adema. 2004. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64: 4024-4029.
36. Rohn, T. A., D. Schadendorf, Y. Sun, X. D. Nguyen, D. Roeder, H. Langen, A. B. Vogt, and H. Kropshofer. 2005. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells. Eur. J. Immunol. 35: 2826-2839.
37. Korbelik, M., and I. Cecic. 1999. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 137: 91-98.
38. Ivarsson, K., L. Myllymaki, K. Jansner, U. Stenram, and K. G. Tranberg. 2005. Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. Br. J. Cancer 93: 435-440.
39. Ali, M. Y., C. F. Grimm, M. Ritter, L. Mohr, H. P. Allgaier, R. Weth, W. O. Bocher, K. Endrulat, H. E. Blum, and M. Geissler. 2005. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43: 817-822.
40. Zerbini, A., M. Pilli, A. Penna, G. Pelosi, C. Schianchi, A. Molinari, S. Schivazappa, C. Zibera, F. F. Fagnoni, C. Ferrari, and G. Missale. 2006. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66: 1139-1146.